Ernest Bueding from Baltimore, MD

Method Of Reducing Or Avoiding The Mutagenic Activity Of Drugs
view source
US Patent:

43282156, May 4, 1982
Filed:

May 9, 1977
Appl. No.:

5/795086
Inventors:

Ernest Bueding - Baltimore MD
Assignee:

The Johns Hopkins University - Baltimore MD
International Classification:

A61K 3171
A61K 3700
A61K 31625
A61K 3147
A61K 31415
US Classification:

424181
Abstract:

A method for reducing or avoiding the transformation of a drug into a mutagenic metabolite in a host to whom the drug is administered, the method comprising administering an antibacterial agent to the host in conjunction with the administration of the drug.

2-Chloro-4-(4-Lower Alkyl-1-Piperazinyl)Benzenemethanol, N.sup..omega. -Oxides And Methods For Their Preparation
view source
US Patent:

42345839, Nov 18, 1980
Filed:

Nov 30, 1978
Appl. No.:

5/965371
Inventors:

Ernest Bueding - Baltimore MD
Leslie M. Werbel - Ann Arbor MI
Donald F. Worth - Ann Arbor MI
Assignee:

Edna McConnell Clark Foundation - New York NY
International Classification:

A61K 31495
C07D29500
US Classification:

424250
Abstract:

2-Chloro-4-(4-lower alkyl-1-piperazinyl)benzenemethanol, N. sup. omega. -oxides and their acid addition salts. These compounds are prepared by oxidizing the corresponding 2-chloro-4-(4-lower alkyl-1-piperazinyl)benzenemethanol. In addition, pharmaceutical compositions comprising said N-oxides and methods for treating schistosomiasis are disclosed.

Ernest Bueding